Combinations of Chemotherapy and PD-1/PD-L1 Inhibitors in Sarcoma

Effect of AGEs-RAGE system on the efficacy of PD-1 inhibitors in the treatment of driver-gene mutation negative advanced non-squamous non-small cell lung cancer

“…In recent years, immunotherapy, which can shift the main target of tumor therapy from tumor cells to the host itself, has attracted wide attention in tumor treatment, with programmed cell death-1 (PD-1) inhibitors being representative drugs (6). As a kind of immune sentinel monoclonal antibody, PD-1 inhibitors have been shown to significantly improve patients' immune function and reduce chemotherapy-induced adverse reactions (7). At present, PD-1 inhibitors have shown strong anti-tumor activity in the treatment of LC, thyroid carcinoma and renal cell carcinoma (8)(9)(10), but their application in the treatment of driver-gene mutation negative nsNSCLC has been rarely reported.…”